Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat

BACKGROUND: We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between these PAH medications. CASE PRESENTATION: A 59-year old male with a history of a...

Descripción completa

Detalles Bibliográficos
Autor principal: Poch, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870744/
https://www.ncbi.nlm.nih.gov/pubmed/27193179
http://dx.doi.org/10.1186/s12890-016-0229-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870744/
https://www.ncbi.nlm.nih.gov/pubmed/27193179
http://dx.doi.org/10.1186/s12890-016-0229-x

Ejemplares similares